Drug Profile
Research programme: protein homeostasis therapeutics - Celgene Corporation/FORMA Therapeutics
Latest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator FORMA Therapeutics
- Developer Celgene Corporation; FORMA Therapeutics
- Class
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Neurodegenerative disorders
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 28 Apr 2019 No recent reports of development identified for research development in Cancer in USA